New gene therapy drug expected to hit market with head-spinning price tag
Share Now on:
The Food and Drug Administration is expected to approve a new gene therapy drug from pharmaceutical company Novartis by the end of May.
- Zolgensma is a treatment for spinal muscular atrophy
- Hundreds of children are born in the United States each year with the genetic, muscle-wasting disorder that kills many sufferers before they reach their second year
- Industry analysts expect the price for the single-treatment therapy to be from $1.5 million to $5 million
- Insurance companies might be reluctant to cover the drug
- Zolgensma represents a coming wave of gene therapy drugs that likely will carry whopping price tags
As a nonprofit news organization, our future depends on listeners like you who believe in the power of public service journalism.
Your investment in Marketplace helps us remain paywall-free and ensures everyone has access to trustworthy, unbiased news and information, regardless of their ability to pay.
Donate today — in any amount — to become a Marketplace Investor. Now more than ever, your commitment makes a difference.